Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges
Executive Summary
Levels of factor VIII in hemophilia A patients after treatment with new gene therapies are variable, a source of investor concern.
You may also be interested in...
Sanofi Genzyme's Sibold On Investing In Blood Disorders And Fending Off Rivals
Sibold talked to Scrip about launching the blood clotting disorder drug Cablivi and finding room in a competitive hemophilia market.
Bayer To Ship Long-Acting Hemophilia Infusion Jivi In A Jiffy
The company believes there is room in the market for its more standard-acting hemophilia A products Kogenate and Kovaltry, as well as a long half-life product like Jivi.
Spark's Gene Therapy Hemophilia Data Give Investors The Jitters
Company explains how it will design upcoming Phase III hemophilia A study of SPK-8011 for success, but some analysts still think it's risky business.